Solid Patent Protection
AC Immune has built a strong Intellectual Property portfolio to protect its technology platforms as well as major disease areas. Patent applications have been filed covering its two technology platforms SupraAntigen™ and Morphomer™, followed by disease-specific patents supporting the basic platform patents. The disease-specific patents cover major disease areas. The company’s freedom to operate regarding its SupraAntigen™ technology and its products under development have been established by U.S. and European opinions. As at 31 march 2013, patents and patent applications from 29 patent families accounting for over 410 national patent applications and 40 granted patents protect the innovative platform technologies of AC Immune and its drug development pipeline.
Continuous effort is placed on filing additional patent applications covering both the base platform technologies and disease-specific applications.